研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

抗氧化剂在化疗诱发的周围神经病变中的治疗潜力:来自临床前和临床研究的证据。

The Therapeutic Potential of Antioxidants in Chemotherapy-Induced Peripheral Neuropathy: Evidence from Preclinical and Clinical Studies.

发表日期:2023 Feb 03
作者: Lin Zhou, Hui Yang, Jing Wang, Yunxing Liu, Yinqiu Xu, Hang Xu, Yong Feng, Weihong Ge
来源: Neurotherapeutics

摘要:

随着癌症治疗技术的进步和患者生存率的提高,人们越来越关注患者在治疗后可能经历的长期不良影响,并出现了对这些持续、进展性和常常是不可逆的不良影响的担忧。化疗是一种潜在的延长生命的治疗方法,而化疗诱导的周围神经病变(CIPN)是其中最常见的长期毒性之一。目前,CIPN的预防和治疗策略仍然是医学所面临的一个难题,并且有大量先前的证据表明氧化损伤参与了CIPN的过程。在本文中,我们侧重于抗氧化剂在抑制CIPN方面发挥作用的防线。我们还提供了不同抗氧化剂(褪黑素、N-乙酰半胱氨酸、维生素、α-硫辛酸、矿物元素、植物化合物、营养抗氧化剂、细胞保护剂和合成化合物)在CIPN治疗中的靶点和临床前和临床研究中的临床前景的更新,强调抗氧化剂作为辅助策略减轻CIPN的巨大潜力。©2023。美国实验神经治疗学协会。
As cancer therapies advance and patient survival improves, there has been growing concern about the long-term adverse effects that patients may experience following treatment, and concerns have been raised about such persistent, progressive, and often irreversible adverse effects. Chemotherapy is a potentially life-extending treatment, and chemotherapy-induced peripheral neuropathy (CIPN) is one of its most common long-term toxicities. At present, strategies for the prevention and treatment of CIPN are still an open problem faced by medicine, and there has been a large amount of previous evidence that oxidative damage is involved in the process of CIPN. In this review, we focus on the lines of defense involving antioxidants that exert the effect of inhibiting CIPN. We also provide an update on the targets and clinical prospects of different antioxidants (melatonin, N-acetylcysteine, vitamins, α-lipoic acid, mineral elements, phytochemicals, nutritional antioxidants, cytoprotectants and synthetic compounds) in the treatment of CIPN with the help of preclinical and clinical studies, emphasizing the great potential of antioxidants as adjuvant strategies to mitigate CIPN.© 2023. The American Society for Experimental Neurotherapeutics, Inc.